This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy of SLT in Patients With Insufficient IOP Control Under Maximum Tolerated Drug Therapy (Eye Drops)

This study has been completed.
Ellex Medical Pty, 82 Gilbert Str., Adelaide, SA 5000
Information provided by:
University of Zurich Identifier:
First received: December 2, 2008
Last updated: December 3, 2008
Last verified: December 2008
Examination and follow-up of efficacy and safety of SLT in patients with unsufficient IOP control despite maximum tolerated topical therapy. In addition, it will be examined whether medical treatment can be reduced after the SLT procedure and whether filtering surgery - as the only remaining option - may be postponed.

Condition Intervention Phase
Glaucoma Device: selective Laser Trabeculoplasty (SLT) Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • IOP lowering effect of SLT in a special patient group [ Time Frame: 1 day, 1 , 3, 6 , 12 months postoperative ]

Enrollment: 30
Study Start Date: January 2008
Estimated Study Completion Date: July 2009
Detailed Description:

SLT (Selective Laser Trabeculoplasty) uses the Nd:YAG-Lasers (wavelength 532nm, Q-switched, frequency-doubled). Thanks to the low laser energy used and the short duration of treatment, only pigmented cells of the trabecular meshwork are targeted and selectively treated. Neighboring, non-pigmented cells and tissue are spared collateral and thermic damage, the architecture of the trabecular meshwork remains intact. The SLT procedure uses less than 1% of the energy of the ALT procedure with an extremely low pulsation duration.

Several studies confirm the effective IOD reduction of SLT and rate the procedure as an relatively safe and effective therapy for glaucoma. Also repeated use of the SLT procedure is considered as meaningful. Meanwhile the SLT procedure is used as primary and supplementary treatment of glaucoma and study confirmed that the SLT procedure was just as effective as administration of Latanoprost in reducing IOD in newly-diagnosed glaucoma.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria: Patients with

  • primary open angle glaucoma (including normal tension glaucoma)
  • pseudoexfoliation glaucoma
  • pigment dispersion glaucoma

Exclusion criteria: previous intraocular surgery closed angle glaucoma pediatric glaucoma inflammatory or uveitic glaucoma unclear view of the trabecular meshwork

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00801658

Zurich, Switzerland
Sponsors and Collaborators
University of Zurich
Ellex Medical Pty, 82 Gilbert Str., Adelaide, SA 5000
Study Director: 01 Studienregister MasterAdmins UniversitaetsSpital Zuerich
  More Information

Responsible Party: Prof. Dr. Dr. Jens Funk, University hospital zurich, eye clinic Identifier: NCT00801658     History of Changes
Other Study ID Numbers: FunkSLT
Study First Received: December 2, 2008
Last Updated: December 3, 2008

Keywords provided by University of Zurich:
Laser treatment
glaucoma treated with eye drops but IOP not controlled

Additional relevant MeSH terms:
Ocular Hypertension
Eye Diseases
Ophthalmic Solutions
Pharmaceutical Solutions processed this record on September 19, 2017